MX2020008523A - Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). - Google Patents
Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).Info
- Publication number
- MX2020008523A MX2020008523A MX2020008523A MX2020008523A MX2020008523A MX 2020008523 A MX2020008523 A MX 2020008523A MX 2020008523 A MX2020008523 A MX 2020008523A MX 2020008523 A MX2020008523 A MX 2020008523A MX 2020008523 A MX2020008523 A MX 2020008523A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- agonist activity
- compound
- receptor
- receptor agonist
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 2
- 206010063661 Vascular encephalopathy Diseases 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 201000000980 schizophrenia Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
- C07C49/252—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
- C07C49/577—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporciona un compuesto en el que el equilibrio de la actividad agonista contra el receptor S1P5 con respecto al receptor S1P1 ha sido mejorado para desarrollar un producto farmacéutico útil para el tratamiento de las enfermedades mediadas por S1P5, tales como la esquizofrenia y la enfermedad de Binswanger y otras enfermedades neurodegenerativas. Este compuesto representado por la fórmula general (V) (en la fórmula, todos los símbolos son como se definieron en la descripción) tiene un equilibrio mejorado de la actividad agonista contra el receptor S1P5 con respecto al receptor S1P1, y por consiguiente puede servir como un agente terapéutico para las enfermedades mediadas por S1P5, tales como la esquizofrenia y la enfermedad de Binswanger y otras enfermedades neurodegenerativas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018029549 | 2018-02-22 | ||
| PCT/JP2019/006637 WO2019163917A1 (ja) | 2018-02-22 | 2019-02-21 | Ｓ１ｐ５受容体作動活性を有する化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008523A true MX2020008523A (es) | 2020-09-18 |
Family
ID=67688486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008523A MX2020008523A (es) | 2018-02-22 | 2019-02-21 | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11198672B2 (es) |
| EP (2) | EP4431157A3 (es) |
| JP (2) | JP7211410B2 (es) |
| KR (1) | KR102823671B1 (es) |
| CN (1) | CN111757869B (es) |
| AU (1) | AU2019224344B2 (es) |
| CA (1) | CA3091216A1 (es) |
| DK (1) | DK3757091T5 (es) |
| ES (1) | ES2993172T3 (es) |
| FI (1) | FI3757091T3 (es) |
| HU (1) | HUE068382T2 (es) |
| IL (1) | IL276656A (es) |
| MX (1) | MX2020008523A (es) |
| MY (1) | MY210277A (es) |
| PH (1) | PH12020551297A1 (es) |
| PL (1) | PL3757091T3 (es) |
| PT (1) | PT3757091T (es) |
| SG (1) | SG11202007896YA (es) |
| TW (2) | TWI821061B (es) |
| WO (1) | WO2019163917A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068382T2 (hu) * | 2018-02-22 | 2024-12-28 | Ono Pharmaceutical Co | SIP5-receptor-agonista aktivitással rendelkezõ 1[[(3S)-3-metil-6-(4(4,4-trifluorbutoxi)-3,4-dihidronaftalen-2-il]metil]azetidin-3-karbonsav neurodegeneratív rendellenességek és rák kezelésére |
| CN114302873A (zh) * | 2019-08-20 | 2022-04-08 | 小野药品工业株式会社 | 具有s1p5受体激动活性的化合物的盐和晶形 |
| WO2024006985A1 (en) * | 2022-07-01 | 2024-01-04 | Autobahn Therapeutics, Inc. | Amide prodrugs and uses thereof |
| WO2025119254A1 (en) | 2023-12-06 | 2025-06-12 | Ono Pharmaceutical Co., Ltd. | Method for preparing dihydronaphthalene derivative |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005020882A (ja) | 2003-06-25 | 2005-01-20 | Matsushita Electric Works Ltd | モータアクチュエータ装置 |
| CN1874991A (zh) | 2003-08-29 | 2006-12-06 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
| EP1661881B1 (en) | 2003-08-29 | 2014-12-17 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding s1p receptor and pharmaceutical use thereof |
| WO2006007448A2 (en) | 2004-06-17 | 2006-01-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| JP2006064757A (ja) | 2004-08-24 | 2006-03-09 | Systec Kyowa:Kk | ディスプレイ固定用スタンド |
| EP2592066B1 (en) * | 2004-12-13 | 2014-12-03 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medical use thereof |
| AU2007212193A1 (en) * | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| UA113507C2 (xx) | 2011-02-07 | 2017-02-10 | Модулятори s1p | |
| ES2852724T3 (es) * | 2014-12-04 | 2021-09-14 | Ono Pharmaceutical Co | Derivados de dihidronaftaleno útiles en el tratamiento de enfermedades mediadas por S1P5 |
| ES2975689T3 (es) * | 2016-01-29 | 2024-07-11 | Ono Pharmaceutical Co | Derivado de tetrahidronaftaleno |
| JP2018029549A (ja) * | 2016-08-26 | 2018-03-01 | キユーピー株式会社 | 苦味低減方法 |
| HUE068382T2 (hu) | 2018-02-22 | 2024-12-28 | Ono Pharmaceutical Co | SIP5-receptor-agonista aktivitással rendelkezõ 1[[(3S)-3-metil-6-(4(4,4-trifluorbutoxi)-3,4-dihidronaftalen-2-il]metil]azetidin-3-karbonsav neurodegeneratív rendellenességek és rák kezelésére |
| CN114302873A (zh) * | 2019-08-20 | 2022-04-08 | 小野药品工业株式会社 | 具有s1p5受体激动活性的化合物的盐和晶形 |
-
2019
- 2019-02-21 HU HUE19756600A patent/HUE068382T2/hu unknown
- 2019-02-21 KR KR1020207023907A patent/KR102823671B1/ko active Active
- 2019-02-21 EP EP24190856.5A patent/EP4431157A3/en active Pending
- 2019-02-21 WO PCT/JP2019/006637 patent/WO2019163917A1/ja not_active Ceased
- 2019-02-21 EP EP19756600.3A patent/EP3757091B9/en active Active
- 2019-02-21 ES ES19756600T patent/ES2993172T3/es active Active
- 2019-02-21 TW TW111146609A patent/TWI821061B/zh active
- 2019-02-21 CA CA3091216A patent/CA3091216A1/en active Pending
- 2019-02-21 MY MYPI2020004122A patent/MY210277A/en unknown
- 2019-02-21 PL PL19756600.3T patent/PL3757091T3/pl unknown
- 2019-02-21 FI FIEP19756600.3T patent/FI3757091T3/fi active
- 2019-02-21 US US16/970,865 patent/US11198672B2/en active Active
- 2019-02-21 CN CN201980014718.7A patent/CN111757869B/zh active Active
- 2019-02-21 SG SG11202007896YA patent/SG11202007896YA/en unknown
- 2019-02-21 PT PT197566003T patent/PT3757091T/pt unknown
- 2019-02-21 JP JP2020501047A patent/JP7211410B2/ja active Active
- 2019-02-21 TW TW108105841A patent/TWI789495B/zh active
- 2019-02-21 DK DK19756600.3T patent/DK3757091T5/da active
- 2019-02-21 MX MX2020008523A patent/MX2020008523A/es unknown
- 2019-02-21 AU AU2019224344A patent/AU2019224344B2/en active Active
-
2020
- 2020-08-11 IL IL276656A patent/IL276656A/en unknown
- 2020-08-20 PH PH12020551297A patent/PH12020551297A1/en unknown
-
2021
- 2021-11-08 US US17/521,004 patent/US12049445B2/en active Active
-
2023
- 2023-01-10 JP JP2023001815A patent/JP7485103B2/ja active Active
-
2024
- 2024-06-14 US US18/744,303 patent/US20240327342A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000037A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| JOP20230235A1 (ar) | عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون | |
| MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| PH12014500326B1 (en) | Heterocyclic derivative and pharmaceutical drug | |
| EP4442695A3 (en) | 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders | |
| AR111693A1 (es) | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga | |
| MX2019008690A (es) | Compuestos espiro heterociclicos como inhibidores de magl. | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| JOP20200263B1 (ar) | مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين d1 | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| EP4494705A3 (en) | Non-peptide oxytocin receptor agonists | |
| BR112020026014A8 (pt) | Derivado de lactama condensado | |
| MX2024013291A (es) | Metodos para tratar trastornos neurodegenerativos | |
| EP4285998A3 (en) | Glycolipids and pharmaceutical compositions thereof for use in therapy | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| PH12020500233A1 (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical |